Biomarker Discovery for Early Disease Detection & Treatment Guidance

Existing cancer diagnostics often result in delays and misdiagnoses. Eviive’s innovative solution combines state-of-the-art extracellular vesicles (EVs) analysis with advanced machine learning to ensure rapid and accurate results. The UZH-spinoff can detect diseases very early and predict if a patient will respond to the standard treatment, leading to more effective and timely interventions. This pioneering approach is set to transform patient outcomes, expedite the advancement of precision medicine, and enhance global patient access to next-generation diagnostics.